The aim of this study was to evaluate the efficacy and safety of gabapentin in patients with learning disabilities and resistant epilepsy, comparing the effects of gabapentin with lamotrigine on efficacy, behaviour and mood.
INTRODUCTION
Epilepsy is common amongst the learning disabled population, especially those with severe or profound degrees of learning disabilities 1 . The risk of developing a seizure disorder increases with the severity of learning disability. Epilepsy occurring in people with learning disabilities can be particularly difficult to treat and assess. A large proportion of patients with learning disabilities continue to have poorly controlled seizures despite the use of two or more antiepileptic drugs (AEDs) 2 . In addition, the common coexistence of behavioural and psychiatric disorders can lead to difficulty in assessing treatment outcome, with such disorders often being attributed to AED treatment. This has lead to recommendations for the assessment of AEDs to include behavioural measures 3 .
There have been few well conducted clinical studies investigating the impact of the newer generation of antiepileptic drugs on seizure control and behaviour in people with epilepsy and learning disabilities. Therefore this trial, which involves a significant number of patients with learning disabilities. Therefore this trial, which involves a significant number of patients with learning disabilities and epilepsy, is invaluable in providing real data to assist in the management of this population. Both gabapentin (Neurontin) and lamotrigine (Lamictal) are newer generation AEDs first licensed in the early 1990s. Both are indicated for addon treatment of partial seizures with or without secondary generalization. Bhaumik et al. 1997 4 , compared both these AEDs along with vigabatrin as addon treatment in adults with learning disabilities and epilepsy, in a small retrospective casenote study. The results of this analysis demonstrated that gabapentin reduced seizure frequency by greater than 50% in 56% of patients compared to 43% of patients taking lamotrigine. However firm conclusions cannot be drawn from this study as it was not a direct prospective comparison and the sample size was too small.
The aim of this study was to evaluate the efficacy and safety of gabapentin, together with its effects on behaviour and mood, in a patient group with learning disabilities whose epilepsy was uncontrolled on current therapy, as part of a randomized controlled trial. Lamotrigine was selected as the comparator drug.
MATERIALS AND METHODS
One hundred and nine learning disabled patients suffering from refractory partial seizures with or without secondary generalization, including a small number of patients who were entered with other seizure types, were recruited into the study. This was a multicentre study conducted with 44 investigators from the UK † . Permission for the study was obtained from the local research ethics committees. Consent was obtained either from the patient or from a patient's relative, guardian or carer and an independent witness. The study population comprised either outpatients or inpatients of specialist hospitals, with an identified key worker/carer who was available for the trial, able to complete the carer rating scales, and to keep a record of seizures.
Patients were eligible for the study if they were aged 12 years and over, of either sex, and had a localization-related epilepsy which was not satisfactorily controlled by their existing antiepileptic medication 5 . In order to fulfil study criteria the subjects had to be taking one, two or three standard AEDs (not including gabapentin or lamotrigine) but still not achieving satisfactory seizure control. A minimum of four seizures in each 28 day period and no seizure free 28 day period in the preceding 3 months was required for entry. Patients had to have a degree of learning disability and to meet any level of the DSM-IV criteria for mental retardation 6 .
The study exclusion criteria included individuals who had had primary generalized seizures, symptomatic generalized epilepsy or a history of nonepileptic seizures. Concurrent therapy with antacids or a recent participation in any clinical trial was not allowed. Women were ineligible if they were pregnant or lactating or of child-bearing potential and sexually active and not practising a reliable method of contraception. A know hypersensitivity to gabapentin or lamotrigine, or significant renal or hepatic dysfunction, also excluded enrolment. Patients on a stable dose of monoamine oxidase inhibitors or antidepressants were allowed to enter the study, providing that this medication was maintained at a constant dose throughout the study. Intermittent use of benzodiazepines as rescue medication, for example rectal diazepam, was also permitted.
Design
There was an initial baseline period of 8 weeks followed by a titration period of up to 14 weeks. At visit B1 a questionnaire was completed about the seizure disorder in order to prevent patients with generalized epilepsies from being randomized into the study. The treatment was then evaluated for a minimum of 10 weeks (Fig. 1) .
Medication was randomized in block sizes of six, with each patient number being unique. Patient numbers were assigned sequentially and this determined the treatment the patient would receive.
Dosing schedule
Patients were randomized to receive either gabapentin or lamotrigine as add-on therapy to their existing AED therapy (between one and three AEDs). The dosages of the study drugs were increased over 14 weeks at the investigator's discretion to a maximum of 3600 mg gabapentin (taken in three divided doses) and 400 mg lamotrigine (taken in two divided doses). For patients taking concurrent sodium valproate the lamotrigine dose was 200 mg.
Assessments
Seizures were recorded in diaries and frequencies per 28 days calculated. The reduction in seizure frequency between the baseline period and the last 8 weeks of the treatment period was assessed using the Rratio (statistical transformation of the seizure frequencies to provide normally distributed data). R-ratio = (T − B)/(T + B) where T and B are the seizure frequencies per 28 days during treatment and baseline, respectively. Additionally, patients whose seizure frequency was reduced by 50% or more were classified as responders. Patients whose seizure frequency was reduced by less than 50% and those withdrawing for treatment-related reasons were classified as nonresponders.
Mood, behaviour and dependency were assessed by: † A complete list of all participating investigators is provided at the end of the paper. (1) Key Carer-rated Visual Analogue Scales (devised by Parke Davis).
(2) Crichton Royal Behavioural Rating Scale 7 .
(3) Whelan and Speake Rating Scale 8 .
(4) Physician's Global Rating Scale (5 point scales) (devised by Parke Davis).
The Key Carer Visual Analogue Scale (carer rating) is used to assess carer outcome 9 . The Crichton Scale covers relevant areas indicating functionality whereas the Whelan and Speake Rating Scale assesses behavioural disturbance.
Safety
Safety and tolerability were assessed by adverse event reports and by the number of patients withdrawing due to adverse events. No laboratory assessments were required by the protocol to be carried out during the study.
Statistical methodology
All patients randomized to a study treatment and who took at least one dose of study medication were used in the analysis. The frequency of seizures was compared by analysis of variance of the R-ratio. The protocol assumed a standard deviation of the R-ratio of 0.2526, requiring 100 patients per treatment group to attain 80% power to detect a difference of 0.1 in the R-ratio as a statistically significant difference (P ≤ 0.05).
As fewer than expected patients were recruited, 80% power was achieved for detection of a slightly larger difference of 0.15.
Responder rates for gabapentin and lamotrigine were compared using logistic regression. Group differences in the Key Carer Visual Analogue Scales were assessed using two-sampled t-tests, and changes from baseline were assessed using paired t-tests. Individual aspects and total scores from the Whelan and Speake Rating Scale and Crichton Scale were assessed nonparametrically using the Wilcoxon rank sum test, and the Wilcoxon signed rank test.
All statistical tests were two-sided (P < 0.05). In considering the significance of all tests carried out on the behavioural and carer rating scales, no adjustment was made for multiple comparisons. Thus, results which are borderline significant at 5% have to be treated with caution, as not all the tests are independent and some significant results could have arisen purely by chance due to the number of scales assessed.
RESULTS

Patient population
A total of 109 learning disabled patients were recruited from 44 sites, 83 of which were randomized to treatment (Fig. 2) . Thirty-nine patients entered the titration phase on gabapentin, and 44 on lamotrigine. No patients withdrew during the baseline period of 8 weeks. Thirty-four patients completed the trial in the gabapentin group, and there were 35 completers on lamotrigine. Some patients had been misclassified based on inaccurate information during baseline. These patients were included in all the efficacy analyses. Patient characteristics are shown in Table 1 , with a summary of the seizure types in Table 2 .
Thirty-five patients were evaluated on gabapentin after visit T1, while 38 patients entered the evaluation phase on lamotrigine.
The mean dose of gabapentin during the evaluation phase was 1749 ± 35 mg per day (minimum 400 mg per day, maximum 3600 mg per day). The mean dose for lamotrigine was 207 ± 38 mg per day (minimum 25 mg per day, maximum 400 mg per day).
The most frequently used concurrent antiepileptic medications were carbamazepine and sodium valproate, taken by 69.9% and 65.1% of trial patients, respectively. In addition, a further nine other AEDs were taken concurrently, diazepam (13.3%) phenytoin (12%), clonazepam (10.8%), vigabatrin (7.2%), phenobarbitone (6%), clobazam (3.6%), ethosuximide (2.4%), topiramate (1.2%) and primidone (1.2%). The number of AEDs started before enrolment for each treatment group were very similar, in both groups the majority of patients had taken two AEDs (41% and 50% in the gabapentin and lamotrigine groups, respectively), with approximately the same numbers taking one or three. The study population were all identified as having a learning disability, in addition, the following problems with adaptive functioning were seen. In terms of mobility, 39% of those randomized were either unable to walk, or were only capable of walking with supervision. When considering aspects of dressing and feeding, 72% were unable to dress adequately without a degree of supervision and 59% required a degree of supervision for adequate feeding. The details recorded for each patient at the beginning of the trial also revealed that 30% of those recruited were unable to talk.
The carer ratings by their nature provide a key insight into the dependency of these patients and the degree of supervision that they require. Carer assessment of need for assistance was high, with general attention tending towards poor. Assessment of seizure severity was also high with 59% of the study population considered to experience seizures nearer to severe than mild.
The disabled population recruited into the trial all had epilepsy to varying degrees, median monthly baseline seizure frequency for randomized patients was 13, ranging from 1 to 796.
Efficacy
Seizure control
The percentage of patients achieving a greater than or equal to 50% reduction in seizure frequency on gabapentin was 50%, with a mean reduction in seizures over the course of the study of 51%. Compared to lamotrigine, no statistically significant treatment differences could be identified (48.6% of patients on lamotrigine achieved a greater than 50% reduction in seizure frequency and the mean reduction in seizures were identical).
Three patients (7.7%) on gabapentin and five patients (11.4%) on lamotrigine were seizure free during the evaluation phase. Only one patient was seizure free during the titration period (in the lamotrigine group).
Analysis of the R-ratio (seen in Table 3 ) also demonstrates that gabapentin and lamotrigine achieved equivalent efficacy.
Behaviour
The carer and behavioural scales overall showed improvements in both groups. The measures achieving statistical significance compared to baseline are outlined in Fig. 3 . Despite the high number of behavioural measures assessed, relatively few showed statistically significant differences between treatments, those that did favoured gabapentin (Fig. 3) .
Key Carer/Worker Visual Analogue Scale. The results from the carer ratings were evaluated using the 100 mm visual analogue scales and were tested parametrically using t-tests. No statistically significant differences were detected when comparing treatments. Most scales showed an improvement from baseline (i.e. within-group analysis) with treatment. This improvement was statistically significant (P < 0.05, paired t-test) in the following scales: seizure severity, attention, general health and sleeping pattern improved on gabapentin, whilst only seizure severity improved significantly amongst patients on lamotrigine.
Crichton Royal Behavioural Rating Scale. The results showed a significantly greater improvement on gabapentin than on lamotrigine (P < 0.05) in the measurement of co-operation, communication and restlessness. Total score also improved significantly (P = 0.01) in the gabapentin group but not in lamotrigine patients.
Challenging Behaviour (Whelan and Speake).
Gabapentin was similar to lamotrigine on this scale, and both drugs reduced the level of challenging behaviour as a total score over the duration of the trial.
Physician's Global Rating Scale. The Physician's Global Rating Scale showed statistically significant improvements over baseline (P < 0.01) for challenging behaviour, seizure severity and general health for both treatment groups at both visits T1 and T2, with the exception of general health in the gabapentin group at T1. However, there was an improvement in general health by T2 from gabapentin with a P-value < 0.01.
Adverse events
The overall incidence of adverse events was similar in both treatment groups (62% in gabapentin and 50% in lamotrigine- Table 4 ). Approximately 10% reported serious adverse events on gabapentin and 11% on lamotrigine. Almost twice as many reports were made for gabapentin than for lamotrigine; these can be attributable to some degree to somnolence. Somnolence was experienced by nine patients (23%) during titration, and ataxia by four patients (10%) on gabapentin. However, during the evaluation phase only one instance of somnolence was reported on gabapentin, suggesting that the incidence was restricted to dose titration and resolved after dose stabilization.
During the evaluation phase, the most commonly occurring adverse event was convulsions two patients, one in each treatment group). Not one adverse event was experienced by more than one patient on gabapentin, however, two patients reported cases of respiratory infection on lamotrigine and a further two reported urinary tract infections.
One patient died during this study while being treated with gabapentin. He had two myocardial infractions before the end of titration. The investigator considered these events to be severe in intensity and unlikely to be related to the study drug.
Four patients experienced serious adverse events on gabapentin, while five suffered serious adverse events on lamotrigine. Only one patient experienced a serious adverse event related to treatment. This patient was in the gabapentin group and suffered drowsiness.
Seven patients were withdrawn due to adverse events: three patients in the gabapentin group (8%) and four in the lamotrigine group (9%). One withdrawal on gabapentin due to an adverse event (of vomiting) was considered (probably) related to study drug. Three patients in the lamotrigine group were withdrawn due to related adverse events. Two patients suffered rash and peripheral oedema. The third patient had a rash.
DISCUSSION
This is the first reported randomized trial of an add-on AED in a defined population of individuals with severe epilepsy and learning disability. The results are important and act against a therapeutic nihilism. The study also shows both study drugs to be effective and to have an impact on behaviour. Some differences could be observed between the two AEDs, with more positive differences in behavioural outcomes observed on addition of gabapentin.
The number of patients recruited into the study was lower than anticipated. The difficulties encountered were primarily due to problems associated with enrolling patients with learning disabilities into a clinical trial. Due to the nature of their condition, many patients are unable to co-operate with study procedures themselves, hence successful recruitment lies in the ability to identify a key carer to complete assessments on the patient's behalf. Many patients were excluded from randomization because, on reviewing their seizure history and descriptions, it was felt that it was more likely that they had a generalized rather than a localization-related epilepsy. The original sample size estimation stated in the protocol that 100 patients treatment group would be required in order to give sufficient power to detect a difference of 0.1 in the R-ratio as a primary end-point. Despite recruitment not meeting this initial target, the patient numbers enrolled still provided a good sample size for the adult learning disabled. No previous parallel group randomized studies in learning disabled adults with epilepsy could be identified, however, there have been three other randomized, controlled trials in LennoxGastaut syndrome [10] [11] [12] . These Lennox-Gastaut studies have provided important data, but with more specific, special populations, many in childhood and specific to Lennox-Gastaut syndrome.
Thirty-four patients completed the gabapentin evaluation phase (87.2%) and 35 patients (79.5%) patients completed the lamotrigine evaluation phase. We can thus conclude that the majority of patients tolerated both drugs adequately.
Seizure severity
Overall the analysis of seizure frequency demonstrated that gabapentin showed no differences in the primary efficacy end-point compared to lamotrigine, however, as the sample size was lower than anticipated, it is not possible to statistically state equivalence in terms of efficacy for the two antiepileptic drugs.
The results of the carer rating scale analysis for patients on gabapentin produced a statistically significant positive effect on improving seizure severity, as did the physician's rating scale. The carer rating evidenced improvements in seizure severity for patients on lamotrigine.
Behaviours
Although seizure diaries have become the most widely used assessment measure in clinical practice, simple counts of seizures may not be the only, or the most useful, measure of outcome, even if such diaries could be relied upon to be accurate 13 . Carers of people with learning disabilities are also the most frequent observers, and typically present a range of concerns about epilepsy which extends beyond the number of seizure events. Therefore, systematic elucidation and measurement of these concerns are important since the reduction may be likely to represent significant clinical improvement. This study set out to identify various other useful measures of clinical improvement in this patient group using a variety of rating scales, arguably the most useful of which was the carer rating. This involved each carer completing a visual analogue scale encompassing the following factors: activity level, tiredness, self-care skills, sleeping pattern, mood, challenging behaviour, general health, attention and seizure severity.
General health and sleeping pattern
Significant improvements in general health were recorded in the physician's rating scale for both gabapentin and lamotrigine. In the gabapentin group this finding was supported by the positive effect recorded on both general health and sleeping pattern in the key carer rating scale analysis.
Disruptive behaviour-co-operation, restlessness and attention span Disruptive behaviour can be particularly distressing and tiresome for family and carers of patients with learning disabilities. People with learning disability and refractory epilepsy may be more prone to behavioural problems 14 . Refractory epilepsy can represent more serious underlying brain pathology predisposing the person to behavioural problems 15 . Behavioural consequences of epilepsy and its treatment may be difficult to disentangle 16 . Agitation and general social disruption throughout the day are common problems. Therefore, effective AED treatment, as well as controlling seizures, should also have a beneficial effect on cognitive function and overall patient behaviour.
The variety of scales used in assessing these patients and the analysis of individual elements of these scales may be expected to result in a few significant improvements or deteriorations occurring by chance alone. However, far more significant changes, all of which were improvements, were detected than would be expected due to chance.
Gabapentin showed an improvement in co-operation and restlessness from the CRBRS baseline measures. In addition, the total score change from baseline to treatment end was improved for the gabapentin group but not for lamotrigine. There were significant differ-ences between the two treatments on measures of cooperation, communication and restlessness for the CR-BRS. No negative changes were detected in the Whelan and Speake scale designed to assess aberrant behaviour in the learning disabled. Both gabapentin and lamotrigine reduced the level of challenging behaviour as a total score over the duration of the trial.
The investigator's (physician's) rating demonstrated a significant improvement over baseline in challenging behaviour as well as seizure severity and general health scores, suggesting an overall positive feeling from the physicians involved.
The results from this trial demonstrate that gabapentin and lamotrigine do not exacerbate any of the challenging behaviours observed in this patient population. This has implications for physicians involved in the clinical management of learning disabled patients suffering with epilepsy. Gabapentin and lamotrigine both provide an effective antiepileptic treatment, proven to positively influence seizure severity, whilst not worsening any other parameters (such as challenging behaviour), and with their proven safety profile, are unlikely to induce any other problems.
Adverse events
The adverse events noted for both drugs are similar to those of previous reviews and those outlined in their respective product characteristics summaries. Both drugs have consistently demonstrated excellent tolerability, this is supported further in learning disabled patients by the results of this trial.
The number of patients with adverse events considered associated to treatment by the investigator was 33% in the gabapentin group and 25% in the lamotrigine group.
Somnolence and ataxia associated with gabapentin treatment was reported by 28% of patients during the titration phase, however, during the evaluation phase only one instance of somnolence was reported. This illustrates that the majority of these adverse events seen with gabapentin abate once the dose is stabilized (Table 5). The number of patients withdrawing from the study due to adverse events was particularly modest for this patient group. Only seven patients withdrew (three in the gabapentin and four in the lamotrigine group).
CONCLUSIONS
The reductions in seizure frequency observed in this study prove that both gabapentin and lamotrigine are effective AEDs for patients with epilepsy and learning disabilities. Improvements in seizure control were the same for both treatment groups.
The safety profiles of gabapentin and lamotrigine were consistent with those seen in previous trials providing further evidence to confirm the good tolerability of both of these drugs in a patient population that is often described as prone to drug-related adverse events. Side effects with gabapentin were mainly confined to the titration phase, and once the maintenance dose was reached, fewer problems were seen.
Behavioural rating scales suggest improvements in co-operation, communication and restlessness for patients on gabapentin when compared to lamotrigine. With both drugs a number of other positive behavioural trends were noted from baseline.
Gabapentin and lamotrigine both provide effective antiepileptic treatment, proven to positively influence seizure severity, whilst not worsening any other parameters (such as challenging behaviour), and with their proven safety profile, are unlikely to induce any other problems.
This study has shown the positive impact of AEDs on a difficult to control population.
